TUBB3 and non-small cell lung carcinoma: The results of our analysis showed that the negative or low TUBB3 expression was associated with a longer OS than the positive or high TUBB3 expression in NSCLC patients receiving the taxane-based, or vinorebine-based, or both taxane- and vinorebine-based regimens (taxane regimen: HR = 2.06, 95% CI = 1.57–2.72, p<0.001; I2 = 0.0%, P = 0.71 for heterogeneity; vinorebine regimen: HR = 1.45, 95% CI = 1.17–1.79, p = 0.001; I2 = 37.6%, P = 0.19 for heterogeneity; taxane and vinorebine combined regimen: HR = 1.19, 95% CI = 1.01–1.41, p = 0.038; I2 = 39.4%, P = 0.18 for heterogeneity, Table 2).